Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

Part of paid clinical trials in Jackson, Mississippi.

Sponsor
University of Mississippi Medical Center
Study ID
NCT02989025
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Preeclampsia (PE)
  • Pregnancy

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 45 Years
Healthy Volunteers
Not accepted

Interventions

  • 17 OHPC — DRUG
    The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.

Study Details

The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.

Key Dates

Start date
May 22, 2017
Status verified
Apr 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.
  • No Intervention: Control
    To determine how close the molecular markers are with 17 OHPC added to the management protocol.

Primary Outcome Measure

Improvement of maternal and perinatal outcomes [ Time Frame: Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Winfred L. Wiser HospitalJacksonMississippi39216
Babbette LaMarca, PhD
[email protected]
(601)815-1430
Sheila Belk, MSCI
[email protected]
(601)984-1690

Find similar trials in Jackson, MS

By research site
Winfred L. Wiser Hospital· Jackson, MS

Related Studies